In 1999 we successfully used a transcript-based discovery approach to identify early detection markers for ovarian cancer [1].
Because breast cancer marker research has focused mainly on prognosis [5], there are few comprehensive studies to identify early detection markers.
Researchers are aggressively trying to identify early detection methods and explore the factors contributing to diabetes related heart disease.
A case control study was conducted to identify early detection indicators of medical disputes in the surgical treatment of liver cancer through Delphi consultation and logistic regression on the basis of which interventions were undertaken to prevent potential cases.
The objective of this study was to evaluate and compare visible and near infrared detection methods for identifying early non-cavitated ex vivo occlusal demineralization.
There should be an effective treatment or intervention for patients identified through early detection, with evidence of early, rather than late, treatment leading to better outcomes.
Small tumors identified using early detection strategies may thus be too small to excise a specimen with enough RNA for microarray analysis.
No randomized controlled trials were identified evaluating early detection of diabetes mellitus in pregnancy versus standard screening (glucose challenge test between 24th to 28th week of gestation) in pregnancy.
Recently, a number of biomarkers have been identified for early detection of GDM, such as sex hormone binding globulin (SHBG) [ 28] and placental growth hormone (PGH) [ 29], which are related to pregnancy, as well as free fatty acids [ 30], adiponectin [ 31, 32], and follistatin-like-3 [ 33] which correlate with obesity and lipid metabolism.
Proteomics enable the analysis of thousands of modified or unmodified proteins simultaneously and has become increasingly popular for identifying biomarkers for early detection, classification and prognosis of tumors, in addition to pinpointing targets for improved treatment outcomes.
